The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients: a Prospective Cohort Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 May 2016
At a glance
- Drugs Febuxostat (Primary)
- Indications Cardiovascular disorders; Hyperuricaemia
- Focus Therapeutic Use
- 05 May 2016 Planned End Date changed from 1 Feb 2016 to 1 Jan 2017.
- 05 May 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jan 2017.
- 05 May 2016 Status changed from recruiting to active, no longer recruiting.